Rapid Micro Biosystems to Participate in the Stifel 2024 Healthcare Conference

LEXINGTON, Mass., Nov. 08, 2024 (GLOBE NEWSWIRE) — Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Stifel 2024 Healthcare Conference.

Rob Spignesi, President and CEO, and Sean Wirtjes, CFO, are scheduled to participate in a 30-minute question-and-answer session with the host analyst on Monday, November 18, 2024 at 11:30 a.m. Eastern Time.

A live webcast will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay after the event.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on Twitter at @rapidmicrobio or on LinkedIn.

CONTACT: Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
mbeaulieu@rapidmicrobio.com

Media Contact:
media@rapidmicrobio.com

Staff

Recent Posts

EDETEK Recognized as the highest Major Contender in Everest Group’s 2024 Clinical Data and Analytics Platforms PEAK Matrix® Assessment

PRINCETON, N.J., Nov. 13, 2024 /PRNewswire/ -- EDETEK, Inc., a leading global provider of specialized…

4 hours ago

St. Joseph’s Health Wins National Patient Safety Award

Total Systems Safety assessment earns St. Joseph's Health facilities the 2024 Safety Excellence Award from…

4 hours ago

Raintree Adds Elite Healthcare Tech SaaS Product and Financial Leaders to Executive Team

Jeff Neunsinger (CFO) and Tara Clem (CPO) Join Raintree Systems to Drive Financial Strategy and…

4 hours ago

QuikMedic and MyCare Medical Group Launch Partnership

CLEARWATER, Fla., Nov. 13, 2024 /PRNewswire/ -- QuikMedic is continuing its national expansion by launching…

4 hours ago